Clinical Trials on Chronic Plaque Type Psoriasis

Total 4620 results

Idera Pharmaceuticals, Inc.

Completed

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis | Actively Extending Plaque Psoriasis

United States
Novartis Pharmaceuticals

Not yet recruiting

Modifying PEST for Psoriatic Arthritis Screening (ScreenX)

Plaque Psoriasis | Psoriatic Arthritis
Eli Lilly and Company

Active, not recruiting

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Plaque Psoriasis | Psoriatic Arthritis

India
Wake Forest University

Completed

Thalidomide in the Treatment of Chronic Plaque Psoriasis.

Psoriasis, Plaque-type

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)

Plaque-type Psoriasis

United States, Austria, Germany, France, Japan, Canada, Slovakia, India
AbbVie (prior sponsor, Abbott)

Withdrawn

Post Marketing Observational Study on Venezuelan Patients With Psoriasis

Moderate to Severe Chronic Plaque Psoriasis
Novartis Pharmaceuticals

Completed

Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)

Plaque-type Psoriasis

Germany, United States, France, Estonia, Canada
Novartis Pharmaceuticals

Completed

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)

Chronic Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Novartis Pharmaceuticals

Completed

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Estonia, France, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Soligenix

Recruiting

Topical SGX302 for Mild-to-Moderate Psoriasis

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

United States
Pierre Fabre Dermo Cosmetique

Completed

An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy (PAP)

Chronic Pruritus Due to Plaque Psoriasis

Spain, France
Icahn School of Medicine at Mount Sinai
Bausch Health Americas, Inc.

Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Plaque Psoriasis | Palmoplantar Psoriasis

United States
LEO Pharma

Completed

Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation

Plaque Psoriasis | Psoriasis Vulgaris

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Moderate to Severe Plaque-type Psoriasis

United States, Colombia, Estonia, Japan, Taiwan, Israel, Canada, Lithuania, Argentina, Latvia, Iceland, Mexico
Novartis Pharmaceuticals

Completed

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN)

Moderate to Severe Plaque-type Psoriasis

Germany
AbbVie

Recruiting

Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece (REDEFINE)

Psoriasis | Moderate Plaque Psoriasis | Moderate Psoriasis

Greece
Narayana Medical College & Hospital

Unknown

Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.

Severe Plaque Type Psoriasis

India
Janssen Research & Development, LLC

Active, not recruiting

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (VISIBLE)

Plaque Psoriasis | Scalp Psoriasis

United States, Canada
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
Azora Therapeutics Australia Pty Ltd

Active, not recruiting

Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis

Plaque Psoriasis | Nail Psoriasis

Australia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

Plaque Psoriasis | Nail Psoriasis
Paul Steven Yamauchi, MD, PhD
Janssen Services, LLC

Unknown

A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

Plaque Psoriasis | Scalp Psoriasis

United States
University of California, San Francisco

Terminated

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

Plaque Psoriasis | Psoriasis Vulgaris

United States
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Plaque Psoriasis | Nail Psoriasis
Icahn School of Medicine at Mount Sinai
UCB Pharma; Psoriasis Treatment Center of Central New Jersey

Recruiting

Bimekizumab in Plaque Psoriasis

Plaque Psoriasis

United States
Almirall, S.A.

Recruiting

A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults (PRO-SCALP)

Plaque Psoriasis

Germany, Spain, United Kingdom
Bio-Thera Solutions

Recruiting

Clinical Study of Stage IV Psoriasis in Children With Geleli

Plaque Psoriasis

China
Microbio Co Ltd

Not yet recruiting

Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Plaque Psoriasis

Plaque Psoriasis
Shanghai Yueyang Integrated Medicine Hospital
Shanghai Skin Disease and Venereal Disease Hospital

Not yet recruiting

Sequential Treatment of Psoriasis With Traditional Chinese and Western Medicine

Plaque Psoriasis
Mindera Health

Not yet recruiting

A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. (MATCH)

Plaque Psoriasis
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (ICONIC-TOTAL)

Plaque Psoriasis

United States, Korea, Republic of, Hungary, United Kingdom, Germany, Poland, Turkey, Canada, Taiwan, Spain, Argentina
Galderma R&D

Active, not recruiting

A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

Psoriasis | Plaque Psoriasis

United States
Meiji Pharma USA Inc.

Completed

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

United States, Canada
Primus Pharmaceuticals
Prosoft Clinical

Completed

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (BDS1307)

Plaque Psoriasis

United States
Primus Pharmaceuticals
Prosoft Clinical

Completed

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Janssen Research & Development, LLC

Active, not recruiting

A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis (FRONTIER 2)

Plaque Psoriasis

United States, Korea, Republic of, Germany, France, Taiwan, Japan, Spain, United Kingdom, Poland, Canada
Bio-Thera Solutions

Completed

Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Arcutis Biotherapeutics, Inc.

Completed

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)

Psoriasis | Plaque Psoriasis

United States, Canada, Dominican Republic
Bioeq GmbH

Completed

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis (VESPUCCI)

Plaque Psoriasis

Poland, Estonia, Ukraine, Georgia
UCB Biopharma SRL

Completed

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

Plaque Psoriasis

Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
Dermavant Sciences GmbH
IQVIA Biotech

Completed

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

Plaque Psoriasis

United States, Canada
Durect
Therapeutics, Inc.

Completed

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Galderma R&D

Completed

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

Plaque Psoriasis

United States
Galderma R&D

Completed

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Plaque Psoriasis

United States
Dermavant Sciences GmbH

Completed

Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Plaque Psoriasis

United States
Amgen

Completed

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

Plaque Psoriasis
Pfizer

Completed

Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Plaque Psoriasis

Iraq
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis (MATURE)

Plaque Psoriasis

Spain, Germany, United States, Iceland, Canada, Poland

3

Subscribe